For part of this study, we are collecting information from patients that have been
experiencing the symptoms mentioned above. We are taking this information and creating a
chest pain registry to follow trends and compare different patients having similar symptoms.
We hope to gain insight into the quality of life, symptoms, and cardiac events of those who
are having similar symptoms. The type of information we will collect includes: demographics,
quality of life, levels of anxiety related to angina pain and cardiac events occurring
within a 2 year period of time.
In addition, we are performing a cardiac stress MRI for research purposes to look at the
blood flow in the small vessels in your heart. During the stress cardiac MRI, we will give
you a medication called Regadenoson (Lexiscan) which "stresses" your heart by dilating the
blood vessels to your heart. This drug is approved by the U.S. Food and Drug Administration
(FDA) for this purpose. We will then be able to measure the myocardial perfusion reserve
(MPR) which is a measure of blood flow through the small blood vessels to see if an abnormal
MPR and small blood vessel disease is associated with an increased risk of cardiovascular
events, such as heart attack. At this point, there is no specific therapy for small vessel
disease. In addition we have phase II of this study which is to determine if exercise and
intensive medical therapy together compared to intensive medical therapy alone improves pain
from the heart and improves overall quality of life.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Virginia
Collaborators:
Astellas Pharma Global Development, Inc. National Heart, Lung, and Blood Institute (NHLBI)